























11. Hattersley M, Rhyasen G, Yao Y, Dulak A, Wang W, Petteruti P, et al. Therapeutic activity of bivalent BRD4 inhibitor AZD5153 in hematological cancers [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16–20; New Orleans, LA Abstr nr 4705.
12. Rhyasen G, Yao Y, Dulak A, Castriotta L, Jacques K, Hattersley M, et al. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16–20; New Orleans, LA Abstr nr 1971.
13. Rhyasen G, Hattersley M, Yao Y, Dulak A, Wang W, Petteruti P, et al. AZD5153: a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies. *Mol Cancer Ther* 2016 Aug 29. pii: molcanther.0141.2016. [Epub ahead of print].
14. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. *Proc Natl Acad Sci U S A* 2011;108:16669–74.
15. Coudé M-M, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. *Oncotarget* 2015;6:17698–712.
16. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. *Nature* 2011;478:524–8.
17. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. *Cell* 2013;153:320–34.
18. Sengupta D, Kannan A, Kern M, Moreno MA, Vural E, Stack B, et al. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma. *Epigenetics* 2015;10:460–6.
19. Devaraj SGT, Fiskus W, Shah B, Qi J, Sun B, Iyer SP, et al. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. *Leukemia* 2016;30:504–8.
20. Chen R, Yik JHN, Lew QJ, Chao S-H. Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer. *Biomed Res Int* 2014;2014:232870.
21. Gilham D, Wasiak S, Tsujikawa LM, Halliday C, Norek K, Patel RC, et al. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. *Atherosclerosis* 2016;247:48–57.
22. Nicholls SJ, Gordon A, Johansson J, Wolski K, Ballantyne CM, Kastelein JJP, et al. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. *J Am Coll Cardiol* 2011;57:1111–9.
23. Waring MJ, Chen H, Rabow AA, Walker G, Bobby R, Boiko S, et al. Potent and selective bivalent inhibitors of BET bromodomains. *Nat Chem Biol* 2016, in press.
24. Chan CH, Fang C, Qiao Y, Yirilina A, Prinjha RK, Ivashkiv LB. BET bromodomain inhibition suppresses transcriptional responses to cytokine-Jak-STAT signaling in a gene-specific manner in human monocytes. *Eur J Immunol* 2015;45:287–97.
25. Bandukwala HS, Gagnon J, Togher S, Greenbaum JA, Lamperti ED, Parr NJ, et al. Selective inhibition of CD4<sup>+</sup> T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. *Proc Natl Acad Sci U S A* 2012;109:14532–7.
26. Xiao Y, Liang L, Huang M, Qiu Q, Zeng S, Shi M, et al. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking I $\kappa$ B kinase-dependent NF- $\kappa$ B activation in rheumatoid fibroblast-like synoviocytes. *Rheumatology* 2016;55:173–84.
27. Belkina AC, Nikolajczyk BS, Denis GV. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. *J Immunol* 2013;190:3670–8.
28. O'Connor T, Borsig L, Heikenwalder M. CCL2-CCR2 signaling in disease pathogenesis. *Endocr Metab Immune Disord Drug Targets* 2015; 15:105–18.
29. Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. *Oncotarget* 2016;7:28697–710.
30. Schultz TE, Blumenthal A. The RP105/MD-1 complex: molecular signaling mechanisms and pathophysiological implications. *J Leukoc Biol* 2016 Apr 11. pii: jlb.2VMR1215-582R [Epub ahead of print].

# Clinical Cancer Research

## Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors

Tammie C. Yeh, Greg O'Connor, Philip Petteruti, et al.

*Clin Cancer Res* 2017;23:1025-1035. Published OnlineFirst January 10, 2017.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1078-0432.CCR-16-1658](https://doi.org/10.1158/1078-0432.CCR-16-1658)

**Supplementary Material** Access the most recent supplemental material at:  
<http://clincancerres.aacrjournals.org/content/suppl/2017/03/02/1078-0432.CCR-16-1658.DC1>

**Cited articles** This article cites 22 articles, 5 of which you can access for free at:  
<http://clincancerres.aacrjournals.org/content/23/4/1025.full#ref-list-1>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/23/4/1025>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.